- Trial Phase
- Approved
- Time to Market
- Already on the market. First approved June 2020 (NMOSD), with subsequent approvals for IgG4-RD (April 2025) and gMG (December 2025).
- Why 4/10
- UPLIZNA is already approved and commercially launched across three indications with no pending PDUFA or pivotal readout in the next ~12 months. The next catalysts are commercial execution (quarterly sales) and early-to-mid-stage pipeline expansion (Phase 2 lupus, Phase 2/3 AIH, planned Phase 3 CIDP), none of which are hard-dated binary events. Per the rubric, an approved drug with no pending regulatory decision scores 3-5. UPLIZNA is one of Amgen's six growth drivers but Amgen is a large diversified biotech (~$250B market cap), so this single drug drives only a modest share of the stock's overall move.
UPLIZNA has no pending PDUFA or pivotal readout with a hard date in the next 12 months. Watch quarterly sales growth as a commercial barometer, and monitor the Phase 2 lupus data readout and the planned Phase 3 CIDP trial initiation for pipeline-expansion signals. The Zenas obexelimab PDUFA (May 2027) is a competitive overhang, though obexelimab's weaker efficacy data reduce the threat.
Price Chart
Executive Summary
UPLIZNA (inebilizumab-cdon) is a CD19-targeted B-cell-depleting monoclonal antibody from Amgen (NASDAQ: AMGN), approved in the U.S. for three autoimmune indications: neuromyelitis optica spectrum disorder (NMOSD, first approved June 2020), immunoglobulin G4-related disease (IgG4-RD, April 2025), and generalized myasthenia gravis (gMG, December 2025). European approvals followed for gMG (February 2026) and NMOSD (May 2026). Commercial momentum is strong: Q3 2026 sales reached $451 million, up 191% year-over-year, making UPLIZNA one of Amgen's six growth drivers. The drug faces potential future competition from Zenas BioPharma's obexelimab (BLA filed, PDUFA May 2027), though obexelimab's Phase 3 efficacy fell short of UPLIZNA's. Pipeline expansion includes Phase 2 trials in systemic lupus erythematosus and autoimmune hepatitis, plus a planned Phase 3 in chronic inflammatory demyelinating polyneuropathy. As an already-approved, commercially ramping product within a large diversified biotech, UPLIZNA has no near-term binary regulatory catalyst.
How It Works
UPLIZNA is a lab-made antibody that targets and depletes a type of immune cell called B cells (specifically those carrying the CD19 protein on their surface). B cells produce autoantibodies that mistakenly attack the body's own tissues in autoimmune diseases. By removing these B cells, UPLIZNA reduces the harmful immune attack. It is given as an intravenous infusion every six months.
Trial Status
UPLIZNA is FDA-approved for three indications: NMOSD (June 2020), IgG4-RD (April 2025), and gMG (December 2025). The gMG approval was supported by the Phase 3 MINT trial, the largest Phase 3 biologic study in gMG including both AChR+ and MuSK+ patients. The IgG4-RD approval was supported by the Phase 3 MITIGATE trial. Long-term open-label extension data from MITIGATE presented at EULAR 2026 showed zero flares in the first year and 71.4% flare-free, glucocorticoid-free complete remission. Pipeline expansion includes a Phase 2 trial in systemic lupus erythematosus (SLE), a Phase 2/3 MERCURY trial in autoimmune hepatitis (AIH), and a planned Phase 3 trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected to start H2 2026-H1 2027.
The Two-Sided Case
Upcoming Catalysts
- Quarterly sales growth reports as commercial execution barometer
- Phase 2 SLE (lupus) data readout (no hard date announced)
- Phase 2/3 MERCURY autoimmune hepatitis trial data (early stage)
- Phase 3 CIDP trial initiation (expected H2 2026-H1 2027)
- Zenas obexelimab PDUFA date (May 2027) as competitive event
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Amgen PRESS-RELEASE AMGN ·Originating report